TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06780891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephysical therapy
Description: The experimental group is undergoing a tele-assisted therapeutic exercise program (T-TPT/T-FIS), which involves physical exercises aimed at improving cardiovascular fitness, muscle strength, and balance, among others. Participants will complete exercises under virtual supervision and submit progress reports.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational session
Description: The educational session will focus on raising awareness about stroke risk factors, such as hypertension, diabetes, and smoking, while promoting healthy lifestyle changes. The goal is to empower them with the knowledge to reduce stroke risk and improve overall well-being.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational session
Description: The educational session will focus on raising awareness about stroke risk factors, such as hypertension, diabetes, and smoking, while promoting healthy lifestyle changes. The goal is to empower them with the knowledge to reduce stroke risk and improve overall well-being.
Study: NCT06780631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based diabetic foot education based on health promotion model
Description: The first group can access the training at any time and repeat the training thanks to web-based training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face to face diabetic foot education based on health promotion model
Description: Individuals with Type 2 diabetes in the face-to-face training group will receive face-to-face diabetic foot training in line with the training booklet for approximately 45 minutes, one by one.
Study: NCT06780150

Intervention type: DRUG
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered as SC injection as per discretion of the treating physician in accordance with local clinical practice and local labeling.
Study: NCT06782295

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Constrained Condylar bearing
Description: Patients in this intervention will receive a CCK bearing component

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: posterior stabilized bearing
Description: Patients in this intervention will receive a PS bearing component
Study: NCT06780852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetranite for Cranial Flap Fixation (TN-CFF)
Description: Bioresorbable bone adhesive for cranial flap fixation following a craniotomy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetranite for Cranial Flap Fixation (TN-CFF)
Description: Bioresorbable bone adhesive for cranial flap fixation following a craniotomy.
Study: NCT06780800

Intervention type: OTHER
Intervention: The Back Belief Questionnaire Tr (BBQ) and Backs-tr
Description: 200 people will be administered The Back Belief Questionnaire Tr (BBQ) and Backs-tr.

Intervention type: OTHER
Intervention: Backs-tr retest
Description: 100 people will fill in the Backs-tr again after 1 week.
Study: NCT06781645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The system involves a digital table with a tactile and interactive surface, providing several play areas. It simulates a village and offers different types of serious cognitive games: semantic memory
Description: Each patient included will benefit from a series of 6 sessions of cognitive stimulation with the interactive digital table of cognitive games 'Le Village de Verdurable'©, and a series of 6 sessions of 'classic' weekly cognitive stimulation at the rate of one session per week, i.e. without the digital table and using the methods of cognitive stimulation normally used in the department. The weekly session used as a comparator in the usual condition will be a session based on concentration and attention with target finding or error finding. The order in which these 2 series of 6 sessions will be carried out will be defined randomly (by drawing lots) before the start of the trial.
Study: NCT06781593

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light therapy
Description: The intervention consists of 30 minutes of daily exposure to light therapy glasses (active or sham according to randomization) on waking for 2 weeks. The light therapy will be delivered in the patient's home at the same time as CPAP is introduced.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light therapy
Description: The intervention consists of 30 minutes of daily exposure to light therapy glasses (active or sham according to randomization) on waking for 2 weeks. The light therapy will be delivered in the patient's home at the same time as CPAP is introduced.
Study: NCT06780098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R-DXD
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: I-DXD
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: I-DXD
Description: IV Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: IV Infusion
Study: NCT06780787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Rectal Examination
Description: Undergo digital rectal exam

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Biopsy
Description: Undergo biopsy with endoscopic exam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Description: Undergo sigmoidoscopy
Study: NCT06253715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Once daily weight-based dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Once daily weight-based dose
Study: NCT06145490

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Caffeine
Description: Caffeine capsule 250 mg, oral intake

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Caffeine
Description: Caffeine capsule 250 mg, oral intake

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo capsule, oral intake

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo capsule, oral intake
Study: NCT05143190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTR-01
Description: Intravenous recombinant collagen 7
Study: NCT06339658

Intervention type: PROCEDURE
Intervention: Targeted axillary dissection (TAD) by ICG
Description: Use of ICG during the targeted axillary dissection (TAD)

Intervention type: PROCEDURE
Intervention: Targeted axillary dissection (TAD) by Blue patent
Description: Use of Blue patent during the targeted axillary dissection (TAD)
Study: NCT05385835

Intervention type: OTHER
Intervention: Training
Description: A training module was prepared by explaining the theoretical and practical parts of the application of blood pressure measurement from the brachial artery with a slide presentation and an animation video. The knowledge and skills of nurses in blood pressure measurement before education were measured. The training module was delivered to the nurses from the online system. At the end of the two-week training period, the knowledge and skill levels of the nurses will be measured again.
Study: NCT06500936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS
Description: The intervention included two series of SMS messages. First, women of IG received one weekly SMS messages for 2 weeks. Those women that did not register a mammography in SITAM 45 days after the 2nd message, received the second series, consisting of one weekly SMS message over two weeks.
Study: NCT04084678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ralinepag
Description: Oral ralinepag

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral tablets
Study: NCT04890743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy combined with electrotherapy (Convenctional TENS method).
Description: One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Conventional TENS method).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy combined with electrotherapy (Pseudo-acupuncture TENS method).
Description: One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Pseudo-acupuncture TENS method).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy combined with electrotherapy (Trabert ultrastimulation method)
Description: One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Trabert ultrastimulation method).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiotherapy combined with placebo electrotherapy
Description: One of the four groups created during randomization will undergo a unified program of kinesiotherapy and placebo electrotherapy.
Study: NCT05024318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg tobe administered as a 30 minute IV infusion every 21 days for 3 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: 42Gy delivered in 3 fractions
Study: NCT06253715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Once daily weight-based dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: Once daily weight-based dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Once daily weight-based dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Once daily weight-based dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: Once daily weight-based dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Once daily weight-based dose
Study: NCT06051942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Waterjet Treatment
Description: The Aquablation therapy is a minimally invasive, image-guided, heat-free robotic therapy delivered by the AQUABEAM Robotic System. During Aquablation therapy, the AQUABEAM Handpiece is inserted transurethrally into the prostatic urethra. The operating physician then utilizes cystoscopy in conjunction with transrectal ultrasound (TRUS) imaging for real time visualization. The AQUABEAM Robotic System utilizes high-velocity sterile saline waterjet to resect and remove the prostate tissue according to the operating physician's treatment plan.
Study: NCT05378789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nap
Description: ICU nurses can take a 20-mn nap between 2 and 5 am according to a rotation of personal.~Naps will be carried out with the help of a Nap and Up ® cocoon deckchair.
Study: NCT06498102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting: Time Restricted Feeding During 6 Weeks
Description: Thirty-one healthy, young males (age: 27.5±6 years, body mass: 76.5±8.4 kg, and maximal oxygen uptake \[V̇O2max\]: 43.9±6.6 mL/kg/min) were randomly assigned to either TRF (n=14) or control group (n=17). TRF group followed an 16:8 intermittent fasting diet program for 6 weeks. Body composition, insulin sensitivity, resting substrate oxidation, and fat oxidation during cycling at 40% V̇O2max were assessed before and after the diet program.
Study: NCT06497725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teleguidance-facilitated Airway Management
Description: tele-guidence will be provided by an experienced airway expert
Study: NCT05024318

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Ablative Radiotherapy
Description: 42Gy delivered in 3 fractions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrectomy
Description: Partial or total nephrectomy performed 9-12 weeks after first dose of Pembrolizumab

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nephrectomy
Description: Partial or total nephrectomy performed 9-12 weeks after first dose of Pembrolizumab
Study: NCT05933291

Intervention type: DRUG
Intervention: steroid
Description: Moderate- or high-dose steroids

Intervention type: DRUG
Intervention: steroid
Description: Moderate- or high-dose steroids
Study: NCT05645666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Well-being therapy
Description: Well-being therapy is a short-term, organized and problem-oriented treatment program that is based on Riff's psychological well-being model. Its purpose is to help patient in order to improve His/her functions in six dimensions; personal growth, environmental mastery, purposefulness of life, and autonomy, self-acceptance and positive relationships with others Therapists help patients find well-being experiences in their present and past lives and pay attention to these experiences, no matter how small or short they are.
Study: NCT05793762

Intervention type: DEVICE
Intervention: Left virtual mirror therapy task
Description: the participant is seated on a chair facing the screen of the virtual mirror therapy device. both hands resting under the screen. The participant is asked, for each block of 20 seconds, to observe the visual feedback of the virtual left hand on the screen (flexion / extension movements of the fingers at 0.5 Hz).

Intervention type: DEVICE
Intervention: Right virtual mirror therapy task
Description: the participant is seated on a chair facing the screen of the virtual mirror therapy device. both hands resting under the screen. The participant is asked, for each block of 20 seconds, to observe the visual feedback of the virtual right hand on the screen (flexion / extension movements of the fingers at 0.5 Hz).
Study: NCT05123131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab (IV): 10 mg/kg on Days 1, 8, 15, 22, 29 in Cycle 1; from Cycle 2 onwards, it will be given on Days 1, 15, 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib (SQ): 1.3 mg/m² on Days 1, 4, 8, 11, 22, 25, 29, and 32.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide (PO): 25 mg/day (10 mg/day for patients with creatinine clearance \[CrCl\] ≥30 to \<60 mL/min) from Day 1 to Day 14 and from Day 22 to Day 35 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (IV)
Description: Dexamethasone (IV on the days of Isatuximab and PO on other days): 20 mg/day on Days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23, 25, 26, 29, 30, 32, and 33. If patients are ≥75 years old, dexamethasone will be administered on Days 1, 4, 8, 11, 15, 16, 22, 25, 29 and 32.
Study: NCT04714216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Omnipod 5/Horizon HCL system
Description: The Omnipod 5/Horizon HCL system, consists of a disposable insulin infusion pump (or pod), a built-in model predictive control (MPC) insulin dosing algorithm, and a remote Personal Diabetes Manager (PDM) interface, that interact with a Dexcom G6 continuous glucose monitor (CGM) to automatically control insulin delivery based upon real-time glucose values. The PDM component also enables remote interaction with the system, including glucose monitoring as well as insulin dosing management and adjustments.
Study: NCT05953961

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therasphere 90Y
Description: Transarterial Radioembolization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave Ablation
Description: Microwave Ablation
Study: NCT06051539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-001
Description: MR-001 is an autonomous neurorehabilitation system based on the principles of Rhythmic Auditory Stimulation intended to improve walking and ambulation in adult chronic stroke patients. MR-001 is intended to be a prescription use only device for use at home/community. The user operates the MR-001 System autonomously and the therapy progresses automatically once a user engages in a session. The MR-001 system consists of two foot sensors that measure walking, a touchscreen device preloaded solely with a proprietary software application, a headset, and charging equipment. The electronic components are powered by lithium-ion rechargeable batteries. Participants are asked to walk with the device for 3 times per week for 12 weeks. Each walking session is 30 minutes in length.
Study: NCT05398354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active retirement
Description: During the intervention, the sensorimotor training program will have a progressive increase in load, the exercises will be divided into 3 levels of intensity: easy (without external load, during the first 8 weeks), intermediate (application of external load: elastic bands, shin guards and free weights, from the 9th to the 16th week) and advanced (increased external load compared to the previous level, from the 17th to the 24th week).~During the sessions we will still assess the intensity through the subjective perception of effort (RPE) scale. In addition, adherence and control of the level of control through the Physical Activity Enjoyment (PACES) survey applied to participants.
Study: NCT05443399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modality - 3D-2D
Description: Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and generalization as 2D

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modality - 2D-3D
Description: Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 3D

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modality - 2D-2D
Description: Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 2D
Study: NCT05775796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab and Chemotherapy
Description: Serplulimab+Paclitaxel+Cisplatin/Carboplatin Serplulimab+Pemetrexed+Cisplatin/Carboplatin
Study: NCT05096390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib Oral Tablet [Inlyta]
Description: Axitinib 5 up to 10mg twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axitinib Oral Tablet [Inlyta]
Description: Axitinib 5 up to 10mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Pembrolizumab intravenously over 30 min minutes at 200 mg every 3 weeks
Study: NCT06094179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody BAT6026
Description: 300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody BAT6026
Description: 300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody BAT6026
Description: 300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium chloride injection
Description: 300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium chloride injection
Description: 300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium chloride injection
Description: 300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)
Study: NCT05346757

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: miRFec test
Description: The miRFec test actually corresponds to the combination of fecal hemoglobin concentration (ie. FIT) and fecal miRNA expression
Study: NCT01025661

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Chiropractic care
Description: Clinical examinations and treatments were performed at the outpatient clinic. The patients were assessed and treated by research assistants and the clinical care was supervised by state registered chiropractors. The choice of therapy and modality was pragmatic and based on the analysis of different functions such as mobility, tenderness, muscle tension and tone, and each patient's relative symptoms. Chiropractic care included high-velocity and low-amplitude techniques, soft-tissue or myofascial techniques, and arthrokinematic stabilizing exercises or a combination of these. Patients were treated in 1-2 sessions per week during the trial.